Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Jubbonti

- PMLiVE

Sandoz partners with Samsung Bioepis to develop up to five biosimilars

The agreement will expand the pipeline and builds on an existing partnership

- PMLiVE

Sandoz appoints Armin Metzger as President of new global unit

Metzger was most recently Executive VP, Chief Technical Operations Officer at Ferring Pharmaceuticals

- PMLiVE

Amgen agrees to lower prescription drug costs in deal with US government

The company has invested $40bn in US R&D and manufacturing in the past seven years

- PMLiVE

Sandoz launches first and only multiple sclerosis biosimilar in US

The treatment is FDA-approved to treat MS and Crohn’s disease

- PMLiVE

Amgen reports positive results from landmark cardiovascular study

The study found significant reductions of major cardiovascular events in high-risk adults following treatment

- PMLiVE

Sandoz to acquire Just-Evotec Biologics to strengthen biosimilar development and manufacturing capabilities

Acquisition will add in-house continuous manufacturing expertise and expand Sandoz’s biosimilar production capacity

- PMLiVE

Amgen commits $650m to US manufacturing expansion

The investment is expected to generate up to 750 new jobs

- PMLiVE

Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

The phase 3 study included around 2,600 patients

- PMLiVE

Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study

Almost one million new cases of gastric cancer are diagnosed globally every year

EU flag

EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy

An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019

- PMLiVE

FDA unveils new voucher programme to accelerate drug review process

The programme is designed to reduce the review time for companies supporting US national interests

- PMLiVE

Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD

Immunoglobulin G4-related disease affects approximately 20,000 people in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links